Name
OÜ Genorama
Registry code
11538292
VAT number
EE101259116
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
30.09.2008 (16)
Financial year
01.01-31.12
Capital
2 556.00 €
Activity
72111 - Research and experimental development on biotechnology
250 074 €
25 048 €
10%
1 663 €
(estimate is approximate)
269 132 €
3
Submitted
No tax arrears
9%
9%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| OÜ Asper Biolab 11538286 | 100% - 2 556.00 EUR | - | - | |
| Hardi Tamm 09.10.1974 (50) | - | Board member | Indirect ownership | |
| Andrei Sõritsa 25.11.1961 (62) | - | - | Indirect ownership | |
| Katrin Tamm 11.05.1974 (50) | - | - | Indirect ownership |
| 2019 03.07.2020 | 2020 28.06.2021 | 2021 30.06.2022 | 2022 26.06.2023 | 2023 27.06.2024 | |
|---|---|---|---|---|---|
| Total Revenue | 121 831 € | 140 756 € | 209 986 € | 280 749 € | 250 074 € |
| Net profit (loss) for the period | 1 532 € | 4 618 € | 34 753 € | 65 970 € | 25 048 € |
| Profit Margin | 1% | 3% | 17% | 23% | 10% |
| Current Assets | 55 037 € | 87 336 € | 127 266 € | 169 412 € | 66 915 € |
| Fixed Assets | 255 379 € | 249 210 € | 248 394 € | 237 471 € | 224 011 € |
| Total Assets | 310 416 € | 336 546 € | 375 660 € | 406 883 € | 290 926 € |
| Current Liabilities | 16 673 € | 23 977 € | 45 138 € | 159 211 € | 21 794 € |
| Non Current Liabilities | 155 000 € | 169 208 € | 152 408 € | 3 588 € | 0 € |
| Total Liabilities | 171 673 € | 193 185 € | 197 546 € | 162 799 € | - |
| Share Capital | - | - | - | - | - |
| Equity | 138 743 € | 143 361 € | 178 114 € | 244 084 € | 269 132 € |
| Employees | 2 | 3 | 2 | 3 | 3 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 40 941.23 € | 9 227.43 € | 8 850.11 € | 9 |
| 2023 Q4 | 53 982.69 € | 9 489.6 € | 8 203.93 € | 8 |
| 2023 Q3 | 56 132.53 € | 9 267.77 € | 8 448.34 € | 8 |
| 2023 Q2 | 74 468.2 € | 7 849.45 € | 7 622.67 € | 8 |
| 2023 Q1 | 85 810.67 € | 10 764.94 € | 7 840.83 € | 8 |
| 2022 Q4 | 64 623.61 € | 12 871.35 € | 7 533.39 € | 9 |
| 2022 Q3 | 61 387.46 € | 8 229.76 € | 7 493.67 € | 9 |
| 2022 Q2 | 100 035.05 € | 9 196.2 € | 6 899.33 € | 9 |
| 2022 Q1 | 43 677.77 € | 7 575.21 € | 6 111.94 € | 9 |
| 2021 Q4 | 50 750.24 € | 10 888.95 € | 6 479.73 € | 8 |
| 2021 Q3 | 45 726.7 € | 7 337.89 € | 6 328 € | 10 |
| 2021 Q2 | 70 257.21 € | 13 738.72 € | 6 854.06 € | 10 |
| 2021 Q1 | 71 891.91 € | 16 815.68 € | 7 214.89 € | 10 |
| 2020 Q4 | 27 727.19 € | 7 012.86 € | 6 728.82 € | 11 |
| 2020 Q3 | 25 900.65 € | 5 933.27 € | 4 218.62 € | 11 |
| 2020 Q2 | 22 896.83 € | 5 188.05 € | 5 456.85 € | 11 |
| 2020 Q1 | 26 024.22 € | 5 009.03 € | 5 262.85 € | 11 |
